https://www.selleckchem.com/products/wz4003.html
Currently, there is contradictory evidence regarding the best strategy to follow after discontinuation of a first biological agent in patients with rheumatoid arthritis (RA). We aimed to compare the long-term efficacy of switching to a second tumor necrosis factor inhibitor (TNFi) biopharmaceuticals with other mechanisms of action (non-TNFi) in patients with RA who previously failed a first TNFi. This prospective cohort study analyzed data from 127 patients who discontinued a previous TNFi between 1999 and 2016. Disease activity was asse
Like
Comment
Share
